International AIDS Conference

The Latest

Dual Maintenance Therapy With Dolutegravir + Rilpivirine

In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Two-Drug HIV Regimen of Dolutegravir and Lamivudine Controls HIV in a Small Study

Researchers reported that a two-drug combination of the integrase inhibitor dolutegravir (Tivicay) with the NRTI lamivudine (Epivir) produced a sustained reduction in viral loads to less than 50 copies in 18 out of 20 people.

By Project Inform

Once-Daily Raltegravir and Dolutegravir-Based Dual-Drug Regimen Show Promise

On behalf of IFARA, Fred Schaich spoke with Pedro Cahn, M.D., Ph.D., about two late-breaking studies presented at this year's International AIDS Conference and about global funding for HIV.

By Barbara Jungwirth

Can a Two-Drug Treatment Regimen Keep HIV Under Control?

An antiretroviral regimen consisting of just two drugs -- dolutegravir and lamivudine -- led to sustained viral suppression for most people starting HIV treatment for the first time, according to findings from a small study presented in a late-breake...

By Liz Highleyman for BETA

Dual Therapy With Dolutegravir + 3TC Keep Viral Load Undetectable: 48-Week Results From PADDLE Study

Updated results from the PADDLE study are encouraging for the likelihood of dolutegravir + 3TC (lamivudine) being a durable option.

By Simon Collins for HIV i-Base

Dolutegravir Is Superior to Boosted Atazanavir in Women in the ARIA Study

Dolutegravir-based ART was superior to a boosted atazanavir-based regimen in treatment naive women at 48 weeks, according to data from the ARIA study presented at AIDS 2016.

By Polly Clayden for HIV i-Base

Dolutegravir Superior in Women-Only Study

On behalf of IFARA, Fred Schaich spoke with Kimberly Smith of ViiV Healthcare at this year's International AIDS Conference about 48-week data from the ARIA study of drug efficacy in women with HIV.

By Barbara Jungwirth